SAB Biotherapeutics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, SAB Biotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of $11.18. The average 1-year stock price forecast is 199.73% higher than the current stock price, while the lowest is $6.00 (+60.86%) and the highest is $16 (+328.95%).

Price Target: $11.18 (+199.73%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$6.00	$11.18	$12	$16
Change	+60.86%	+199.73%	+221.72%	+328.95%

Analyst Ratings

The average analyst rating for SAB Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	8	8	8	8	10	10
Buy	0	0	0	0	0	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	10	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Eliana Merle Barclays	Barclays	Buy Initiates $13	Buy	Initiates	$13	+248.53%	Jun 24, 2026
Keay Nakae Chardan Capital	Chardan Capital	Buy Reiterates $14 → $16	Buy	Reiterates	$14 → $16	+328.95%	Jun 17, 2026
Albert Lowe Craig-Hallum	Craig-Hallum	Buy Maintains $6	Buy	Maintains	$6	+60.86%	Jun 16, 2026
Samantha Semenkow Citi	Citi	Buy Reiterates $11	Buy	Reiterates	$11	+194.91%	Jun 16, 2026
Leland Gershell Oppenheimer	Oppenheimer	Buy Reiterates $14	Buy	Reiterates	$14	+275.34%	Jun 15, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

62.50K

EPS This Year

-1.28

from -0.81

EPS Next Year

-0.98

from -1.28

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	60.88M	23.90M	2.24M	1.32M	-	-
Operating Income	-13.39M	-28.92M	-38.08M	-42.91M	-48.95M	-82.59M
Net Income	-17.14M	-18.74M	-42.19M	-34.11M	13.27M	-79.59M
EPS	-	-	-	-	-0.81	-1.28
Free Cash Flow	3.28M	-14.29M	-17.95M	-22.10M	-21.99M	-63.67M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.06
Avg	-1.28
Low	-1.88

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-